BioCentury | Mar 2, 2009
Company News

Cellatope Corp, Cypress Bioscience deal

...Cypress acquired Cellatope's cell-bound complement activation products (CB-CAP) technology for $2 million in cash and $3...
...expects to launch the test in mid-2010. Cypress markets Avise pharmacogenetics tests for rheumatoid arthritis. Cellatope...
Items per page:
1 - 1 of 1
BioCentury | Mar 2, 2009
Company News

Cellatope Corp, Cypress Bioscience deal

...Cypress acquired Cellatope's cell-bound complement activation products (CB-CAP) technology for $2 million in cash and $3...
...expects to launch the test in mid-2010. Cypress markets Avise pharmacogenetics tests for rheumatoid arthritis. Cellatope...
Items per page:
1 - 1 of 1